Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications ...

Location: (Salons B,C,D - Lower Level, Hilton Chicago) ...

Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological ...

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR.

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert ...

Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass.--(BUSINESS ...

Advancing U.S.-based cGMP manufacturing to support clinical and future commercial objectives of a novel siRNA therapy ...

TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to ...

A Critical Next Step in Advancing Phio’s PH-762 Program to Treat Cutaneous Carcinomas Phio Pharmaceuticals Corp.

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune ...

By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On April 1st, ...

A recent narrative review looks at the most effective and emerging options for diagnosing and treating basal cell carcinoma.